Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Q3 Revenues up 14 Percent

NEW YORK – Thermo Fisher Scientific reported on Wednesday that its third quarter revenues rose 14 percent year over year.

For the three months ended Oct. 1, the Waltham, Massachusetts-based company reported total revenues of $10.68 billion, up from $9.33 billion a year ago and beating the average Wall Street analyst estimate of $9.91 billion. Organic revenues fell 1 percent, with acquisitions increasing revenue by 20 percent and currency translation decreasing revenue by 5 percent, Thermo Fisher said.

COVID-19 testing revenue was $440 million for the quarter.

Revenues from the life sciences solutions business unit fell 20 percent to $2.96 billion in Q3 2022 from $3.72 billion in Q3 2021. Revenues from the analytical instruments segment rose 9 percent to $1.62 billion from $1.48 billion in the year-ago quarter. Revenues from the laboratory products and biopharma services segment rose 60 percent to $5.59 billion from $3.49 billion. Revenues from the specialty diagnostics segment were down 21 percent to $1.07 billion from $1.36 billion in Q3 2021.

Thermo Fisher's Q3 net income fell to $1.50 billion, or $3.79 per share, from $1.90 billion, or $4.79 per share, a year ago. On an adjusted basis, the company reported EPS of $5.08 per share for the quarter, beating the Wall Street estimate of $4.81 per share.

The company's R&D costs were flat at $351.0 million. Its SG&A expenses rose less than 1 percent to $1.74 billion from $1.73 billion.

Thermo Fisher ended the quarter with cash and cash equivalents of $2.92 billion.

On a conference call following release of the quarterly results, Thermo Fisher Chairman, President, and CEO Marc Casper said the company was raising its full-year guidance to account for the strength of its core business as well as "a modest impact of additional COVID-19 testing," factors that he noted were "more than offsetting the increased foreign exchange headwinds."

The company raised its 2022 revenue guidance to $43.8 billion, up $650 million from $43.2 billion, which would result in 12 percent revenue growth over 2021. It raised its 2022 adjusted EPS guidance from $22.93 to $23.01.

Analysts are expecting revenues of $43.2 billion and earnings per share of $22.95 for the year.

The firm's shares were down 1 percent to $508.00 in Wednesday morning trading on the New York Stock Exchange.

The Scan

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.

Sequencing Analysis Examines Gene Regulatory Networks of Honeybee Soldier, Forager Brains

Researchers in Nature Ecology & Evolution find gene regulatory network differences between soldiers and foragers, suggesting bees can take on either role.

Analysis of Ashkenazi Jewish Cohort Uncovers New Genetic Loci Linked to Alzheimer's Disease

The study in Alzheimer's & Dementia highlighted known genes, but also novel ones with biological ties to Alzheimer's disease.

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.